ANTIVIRAL:
CLOUDBREAK® AVCs

Cidara is developing a new generation of immunotherapeutic antivirals from its Cloudbreak platform that couple potent antivirals to a human antibody fragment. These long-acting, antiviral conjugates (AVCs) directly inhibit viral proliferation while simultaneously engaging the immune system to maximize viral clearance.

Overview

Influenza

HIV, RSV, Coronavirus
And Other Viruses

Cidara’s Cloudbreak antiviral platform is a fundamentally new approach to treating and preventing viral infections. By applying the principles of immuno-oncology to infectious disease, Cidara is creating a new generation of antivirals that stably couple a potent antiviral targeting domain, a small molecule or a peptide, to an effector domain, a proprietary variant of a human antibody fragment (Fc). These long-acting, bispecific AVCs are designed to directly inhibit viral proliferation while simultaneously directing immune-mediated clearance of the virus. The two distinct and complementary mechanisms are designed to maximize antiviral activity of AVCs.

AVC
Viral surface protein target
Viral surface
Natural killer cell surface

AVCs are first being studied for universal prevention and treatment of influenza. IND-enabling studies with lead candidate CD377 are ongoing. Cidara is also advancing preclinical and discovery programs to target additional life-threatening viruses, including RSV, HIV and coronavirus.

Antiviral conjugates (AVCs) are being designed to target:

Influenza

Respiratory Syncytial Virus (RSV)

Human Immunodeficiency Virus (HIV)

Coronavirus & Other Viruses